Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
J Pathol. 2021 Apr;253(4):415-426. doi: 10.1002/path.5606. Epub 2021 Jan 26.
We reported previously that high numbers of mast cells in benign (extra-tumoral) regions of the prostate are associated with worse outcomes after radical prostatectomy including biochemical recurrence and the development of metastases. Herein, with a cohort of 384 men, we performed mast cell subtyping and report that higher minimum number of the tryptase-only (MC ) subset of extra-tumoral mast cells is associated with increased risk of biochemical recurrence (comparing highest to lowest tertiles: HR 2.32, 95% CI 1.37-3.93; P-trend = 0.002), metastases (HR 3.62, 95% CI 1.75-7.47; P-trend 0.001), and death from prostate cancer (HR 2.87, 95% CI 1.19-6.95; P-trend = 0.02). Preliminary RNA sequencing and comparison of benign versus cancer tissue mast cells revealed differential expression of additional site-specific genes. We further demonstrate that the genes CXCR4 and TFE3 are more highly expressed in tumor-infiltrating mast cells as well as other tumor-infiltrating immune cells and in tumor cells, respectively, and represent an altered tumor microenvironment. KIT variants were also differentially expressed in benign versus cancer tissue mast cells, with KIT variant 1 (GNNK ) mast cells identified as more prevalent in extra-tumoral regions of the prostate. Finally, using an established mouse model, we found that mast cells do not infiltrate Hi-Myc tumors, providing a model to specifically examine the role of extra-tumoral mast cells in tumorigenesis. Hi-Myc mice crossed to mast cell knockout (Wsh) mice and aged to 1 year revealed a higher degree of pre-invasive lesions and invasive cancer in wild-type mice versus heterozygous and knockout mice. This suggests a dosage effect where higher numbers of extra-tumoral mast cells resulted in higher cancer invasion. Overall, our studies provide further evidence for a role of extra-tumoral mast cells in driving adverse prostate cancer outcomes. © 2020 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
我们之前报道称,前列腺良性(肿瘤外)区域中大量的肥大细胞与根治性前列腺切除术后的不良结果相关,包括生化复发和转移的发展。在此,我们对 384 名男性进行了肥大细胞亚型分类,并报告说,肿瘤外肥大细胞中仅含有类胰蛋白酶(MC)亚群的最低数量较高与生化复发风险增加相关(比较最高和最低三分位数:HR 2.32,95%CI 1.37-3.93;P-trend=0.002),转移(HR 3.62,95%CI 1.75-7.47;P-trend 0.001),以及死于前列腺癌(HR 2.87,95%CI 1.19-6.95;P-trend=0.02)。初步的 RNA 测序和良性与癌症组织肥大细胞的比较显示出其他特定部位基因的差异表达。我们进一步证明,CXCR4 和 TFE3 基因在肿瘤浸润性肥大细胞以及其他肿瘤浸润性免疫细胞和肿瘤细胞中的表达更高,分别代表了改变的肿瘤微环境。KIT 变体在良性与癌症组织肥大细胞中的表达也不同,在前列腺肿瘤外区域中发现 KIT 变体 1(GNNK)肥大细胞更为普遍。最后,使用已建立的小鼠模型,我们发现肥大细胞不会浸润 Hi-Myc 肿瘤,为专门研究肿瘤外肥大细胞在肿瘤发生中的作用提供了模型。Hi-Myc 小鼠与肥大细胞敲除(Wsh)小鼠杂交并生长至 1 年,发现野生型小鼠比杂合子和敲除小鼠的前侵袭性病变和侵袭性癌症程度更高。这表明存在剂量效应,即肿瘤外肥大细胞数量增加导致癌症侵袭性增加。总体而言,我们的研究为肿瘤外肥大细胞在驱动前列腺癌不良结局中的作用提供了进一步的证据。2020 年英国和爱尔兰病理学会。由 John Wiley & Sons,Ltd. 出版。